Bronchodilator and Antihyperkalemic Effects of Salbutamol (Albuterol) in Neonates and Young Infants

Abstract

Salbutamol (albuterol) is a β₂-agonist used for its bronchodilator activity and for its antihyperkalemic property. Salbutamol was specifically designed for use in infants and children. The preferred route of administration is by a nebulizer because systemic effects are lower than after oral or intravenous administration. Salbutamol is the most widely used bronchodilator in adults and children. When inhaled from metered-dose aerosol, it is easy to use, has a rapid onset of action, and does not have significant adverse effects. Compared with preadministration values, salbutamol yields a significant decrease in resistance and an increase in compliance. Salbutamol can alleviate bronchospasm in infants and children with chronic lung disease such as asthma. The bronchodilator effects of salbutamol are attributed to the R-enantiomer of salbutamol (levosalbutamol). The decrease in airway resistance reflects the relationship between the bronchial smooth muscle and the diameter of the airways. Infants who required intubation and mechanical ventilator support for respiratory syncytial virus-induced respiratory failure had an improvement of lung function following the administration of salbutamol. Nebulized salbutamol has not been reported to have cardiac side effects. Epinephrine was not found to be more efficacious than salbutamol in treating moderately ill infants with bronchiolitis. Hyperkalemia is a fatal disorder that requires treatment. The aim of this review is to summarize the published data on the activities of salbutamol as a bronchodilator and as an antihyperkalemia agent in neonates.

Keywords

albuterol - β-agonist - children - hyperkalemia - mechanism-of-action - neonate - salbutamol

• References

• 1 Ainsworth SB. Neonatal Formulary 7. West Sussex: John Wiley & Sons Ltd; 2015: 464-465
• 2 Zaagsma J, van der Heijden PJ, van der Schaar MW, Bank CM. Comparison of functional beta-adrenoceptor heterogeneity in central and peripheral airway smooth muscle of guinea pig and man. J Recept Res 1983; 3 (1–2) 89-106
• 3 Carstairs JR, Nimmo AJ, Barnes PJ. Autoradiographic visualization of beta-adrenoceptor subtypes in human lung. Am Rev Respir Dis 1985; 132 (3) 541-547
• 4 Melmon KL, Morelli HF, Hoffman BB, Nierenberg DW. Melmon and Morrelli's Clinical Pharmacology. 4th ed. New York, NY: Mc Graw-Hill; 2000
• 5 Torphy TJ, Freese WB, Rinard GA, Brunton LL, Mayer SE. Cyclic nucleotide-dependent protein kinases in airway smooth muscle. J Biol Chem 1982; 257 (19) 11609-11616
• 6 Silver PJ, Stull JT. Phosphorylation of myosin light chain and phosphorylase in tracheal smooth muscle in response to KCl and carbachol. Mol Pharmacol 1984; 25 (2) 267-274
• 7 Church MK, Hiroi J. Inhibition of IgE-dependent histamine release from human dispersed lung mast cells by anti-allergic drugs and salbutamol. Br J Pharmacol 1987; 90 (2) 421-429
• 8 Howarth PH, Durham SR, Lee TH, Kay AB, Church MK, Holgate ST. Influence of albuterol, cromolyn sodium and ipratropium bromide on the airway and circulating mediator responses to allergen bronchial provocation in asthma. Am Rev Respir Dis 1985; 132 (5) 986-992
• 9 Erjefält I, Persson CG. Anti-asthma drugs attenuate inflammatory leakage of plasma into airway lumen. Acta Physiol Scand 1986; 128 (4) 653-654
• 10 Pavia D, Bateman JR, Clarke SW. Deposition and clearance of inhaled particles. Bull Eur Physiopathol Respir 1980; 16 (3) 335-366
• 11 Rhoden KJ, Meldrum LA, Barnes PJ. Inhibition of cholinergic neurotransmission in human airways by beta 2-adrenoceptors. J Appl Physiol (1985) 1988; 65 (2) 700-705
• 12 Jantikar A, Brashier B, Maganji M , et al. Comparison of bronchodilator responses of levosalbutamol and salbutamol given via a pressurized metered dose inhaler: a randomized, double blind, single-dose, crossover study. Respir Med 2007; 101 (4) 845-849
• 13 Maiti R, Prasad CN, Jaida J, Mukkisa S, Koyagura N, Palani A. Racemic salbutamol and levosalbutamol in mild persistent asthma: A comparative study of efficacy and safety. Indian J Pharmacol 2011; 43 (6) 638-643
• 14 Helfrich E, de Vries TW, van Roon EN. Salbutamol for hyperkalaemia in children. Acta Paediatr 2001; 90 (11) 1213-1216
• 15 Young TE, Mangum B. Respiratory drugs. In: Young TE, Mangum B, eds. Neofax: A Manual of Drugs Used in Neonatal Care. 23rd ed. Montvale, NJ: Thomson Reuters; 2010
• 16 Wilkie RA, Bryan MH. Effect of bronchodilators on airway resistance in ventilator-dependent neonates with chronic lung disease. J Pediatr 1987; 111 (2) 278-282
• 17 Rotschild A, Solimano A, Puterman M, Smyth J, Sharma A, Albersheim S. Increased compliance in response to salbutamol in premature infants with developing bronchopulmonary dysplasia. J Pediatr 1989; 115 (6) 984-991
• 18 Yuksel B, Greenough A. Airways resistance and lung volume before and after bronchodilator therapy in symptomatic preterm infants. Respir Med 1994; 88 (4) 281-286
• 19 Yuksel B, Greenough A. Effect of nebulized salbutamol in preterm infants during the first year of life. Eur Respir J 1991; 4 (9) 1088-1092
• 20 Tal A, Bar-Yishay E, Eyal F, Godfrey S. Lack of response to bronchodilator of airway obstruction after mechanical ventilation in the newborn. Crit Care Med 1982; 10 (6) 361-362
• 21 De Boeck K, Smith J, Van Lierde S, Devlieger H. Response to bronchodilators in clinically stable 1-year-old patients with bronchopulmonary dysplasia. Eur J Pediatr 1998; 157 (1) 75-79
• 22 Stefano JL, Bhutani VK, Fox WW. A randomized placebo-controlled study to evaluate the effects of oral albuterol on pulmonary mechanics in ventilator-dependent infants at risk of developing BPD. Pediatr Pulmonol 1991; 10 (3) 183-190
• 23 Kraemer R, Birrer P, Sennhauser FH, Schöni MH. Short-time response characteristics of salbutamol in infants with broncho-pulmonary diseases. Eur J Clin Pharmacol 1988; 34 (4) 339-342
• 24 Pfenninger J, Aebi C. Respiratory response to salbutamol (albuterol) in ventilator-dependent infants with chronic lung disease: pressurized aerosol delivery versus intravenous injection. Intensive Care Med 1993; 19 (5) 251-255
• 25 Ng G, da Silva O, Ohlsson A. Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants. Cochrane Database Syst Rev 2012; 6: CD003214
• 26 Derish M, Hodge G, Dunn C, Ariagno R. Aerosolized albuterol improves airway reactivity in infants with acute respiratory failure from respiratory syncytial virus. Pediatr Pulmonol 1998; 26 (1) 12-20
• 27 Ho L, Collis G, Landau LI, Le Souef PN. Effect of salbutamol on oxygen saturation in bronchiolitis. Arch Dis Child 1991; 66 (9) 1061-1064
• 28 O'Callaghan C, Milner AD, Swarbrick A. Paradoxical deterioration in lung function after nebulised salbutamol in wheezy infants. Lancet 1986; 2 (8521–22) 1424-1425
• 29 Schweich PJ, Hurt TL, Walkley EI, Mullen N, Archibald LF. The use of nebulized albuterol in wheezing infants. Pediatr Emerg Care 1992; 8 (4) 184-188
• 30 Chavasse RJ, Bastian-Lee Y, Richter H, Hilliard T, Seddon P. Inhaled salbutamol for wheezy infants: a randomised controlled trial. Arch Dis Child 2000; 82 (5) 370-375
• 31 Mull CC, Scarfone RJ, Ferri LR , et al. A randomized trial of nebulized epinephrine vs albuterol in the emergency department treatment of bronchiolitis. Arch Pediatr Adolesc Med 2004; 158 (2) 113-118
• 32 Reijonen T, Korppi M, Pitkäkangas S, Tenhola S, Remes K. The clinical efficacy of nebulized racemic epinephrine and albuterol in acute bronchiolitis. Arch Pediatr Adolesc Med 1995; 149 (6) 686-692
• 33 Rieger-Fackeldey E, Reinhardt D, Schulze A. Effects of inhaled formoterol compared with salbutamol in ventilated preterm infants. Pulm Pharmacol Ther 2004; 17 (5) 293-300
• 34 Gappa M, Gärtner M, Poets CF, von der Hardt H. Effects of salbutamol delivery from a metered dose inhaler versus jet nebulizer on dynamic lung mechanics in very preterm infants with chronic lung disease. Pediatr Pulmonol 1997; 23 (6) 442-448
• 35 Fok TF, Lam K, Ng PC , et al. Randomised crossover trial of salbutamol aerosol delivered by metered dose inhaler, jet nebuliser, and ultrasonic nebuliser in chronic lung disease. Arch Dis Child Fetal Neonatal Ed 1998; 79 (2) F100-F104
• 36 Fok TF, Lam K, Ng PC , et al. Delivery of salbutamol to nonventilated preterm infants by metered-dose inhaler, jet nebulizer, and ultrasonic nebulizer. Eur Respir J 1998; 12 (1) 159-164
• 37 Katz RW, Kelly HW, Crowley MR, Grad R, McWilliams BC, Murphy SJ. Safety of continuous nebulized albuterol for bronchospasm in infants and children. Pediatrics 1993; 92 (5) 666-669
• 38 Mhanna MJ, Patel JS, Patel S, Cohn R. The effects of racemic albuterol versus levalbuterol in very low birth weight infants. Pediatr Pulmonol 2009; 44 (8) 778-783
• 39 Mildenberger E, Versmold HT. Pathogenesis and therapy of non-oliguric hyperkalaemia of the premature infant. Eur J Pediatr 2002; 161 (8) 415-422
• 40 Kemper MJ, Harps E, Hellwege HH, Müller-Wiefel DE. Effective treatment of acute hyperkalaemia in childhood by short-term infusion of salbutamol. Eur J Pediatr 1996; 155 (6) 495-497
• 41 Murdoch IA, Dos Anjos R, Haycock GB. Treatment of hyperkalaemia with intravenous salbutamol. Arch Dis Child 1991; 66 (4) 527-528
• 42 Vemgal P, Ohlsson A. Interventions for non-oliguric hyperkalaemia in preterm neonates. Cochrane Database Syst Rev 2012; 5: CD005257
• 43 Malone TA. Glucose and insulin versus cation-exchange resin for the treatment of hyperkalemia in very low birth weight infants. J Pediatr 1991; 118 (1) 121-123
• 44 Hu PS, Su BH, Peng CT, Tsai CH. Glucose and insulin infusion versus kayexalate for the early treatment of non-oliguric hyperkalemia in very-low-birth-weight infants. Acta Paediatr Taiwan 1999; 40 (5) 314-318
• 45 Yaseen H, Khalaf M, Dana A, Yaseen N, Darwich M. Salbutamol versus cation-exchange resin (kayexalate) for the treatment of nonoliguric hyperkalemia in preterm infants. Am J Perinatol 2008; 25 (3) 193-197
• 46 Williams SJ, Winner SJ, Clark TJ. Comparison of inhaled and intravenous terbutaline in acute severe asthma. Thorax 1981; 36 (8) 629-631
• 47 Anderson SD, Seale JP, Rozea P, Bandler L, Theobald G, Lindsay DA. Inhaled and oral salbutamol in exercise-induced asthma. Am Rev Respir Dis 1976; 114 (3) 493-500